N@N

Li Watsek Maintained (ASND) at Buy with Increased Target to $152 on, Apr 28th, 2023

Li Watsek of Cantor Fitzgerald, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $142 to $152 on, Apr 28th, 2023.

Li has made no other calls on ASND in the last 4 months.

There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 1 agrees with Li's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, April 5th, 2023

These are the ratings of the 4 analyists that currently disagree with Li

---

• David Lebowitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $146 on, Wednesday, April 5th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $92 on, Tuesday, April 4th, 2023
• Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $163 on, Tuesday, January 17th, 2023
• Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023

Contributing Sources

---